Is ZYN Better Than Smoking? What FDA Has Actually Said
FDA cleared a reduced-risk claim for 20 ZYN products in June 2026. Here is exactly what the agency authorized, what it did not, and what research shows.
TL;DR: On June 30, 2026, the FDA issued modified risk granted orders for 20 ZYN nicotine pouch products, letting them be marketed with this claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." That is the strongest comparison the FDA has allowed between a nicotine pouch and cigarettes. It is not an approval of ZYN as a product, not a finding that pouches are "safe," and not permission to market ZYN for quitting smoking.
In one sentence: FDA now permits a specific reduced-risk claim for 20 ZYN products in 3 mg and 6 mg, but it has never called nicotine pouches safe, never approved them as medicine, and never authorized them for smoking cessation.
What FDA Has Actually Said About ZYN and Smoking
Three separate FDA decisions matter here, and they are easy to blur together.
January 16, 2025: marketing authorization (PMTA). FDA authorized 20 ZYN products, ten flavors each at 3 mg and 6 mg, to be sold in the United States. Authorization means FDA reviewed Swedish Match's premarket tobacco product applications and concluded that letting the products stay on the market was "appropriate for the protection of the public health."
June 30, 2026: modified risk orders (MRTP). FDA went further and issued risk modification orders for those same 20 products under section 911(g)(1) of the Federal Food, Drug, and Cosmetic Act. This is the decision that answers the "is ZYN better than smoking" question. FDA concluded that Swedish Match had demonstrated the claim is scientifically accurate for these specific products, that consumers understand it, and that marketing the products with the claim would benefit the population as a whole. The orders run for five years and require postmarket surveillance on how people understand and use the claim.
August 21, 2026: ZYN ULTRA (PMTA only). FDA authorized 11 ZYN ULTRA products, the 9 mg line plus ZYN Ultra Smooth 11 mg. These are marketing authorizations without any modified risk claim, so the "lower risk than cigarettes" wording does not apply to them.
That gives ZYN 31 authorized products in the US: 20 from January 2025 and 11 from August 2026. For a product-by-product breakdown, see our FDA authorization scorecard and the ZYN PMTA explainer.
What the Modified Risk Order Does Not Say
The order is narrower than most headlines made it sound.
- Not "FDA approved." Tobacco products are authorized, not approved. Approval is a drug term, and ZYN has not been through that process.
- Not blanket "safe." FDA authorized one claim for specific products. It did not declare pouches harmless, and nicotine itself still carries cardiovascular and dependence risks.
- Not a quit-smoking authorization. That requires a separate pathway with clinical evidence. The modified risk claim is about relative risk for adults who smoke, not about cessation.
- Not class-wide. The claim covers 20 named ZYN products in 3 mg and 6 mg. ZYN ULTRA is not covered. Neither is on! PLUS, VELO, Rogue, Lucy, FRE or any other brand.
- Not free-form wording. Swedish Match may use the authorized sentence, not a rewritten version of it.
Which Brands Have FDA Authorization Today
FDA's tally of authorized nicotine pouch products reached 67 on October 30, 2026, when the agency authorized 24 VELO Mini Pouch and VELO Mini Pouch 2 products at 4 mg. Rogue, Lucy and FRE have submitted applications but hold no marketing authorization as of November 2026. Only ZYN holds modified risk orders; VELO and on! PLUS hold marketing authorization without a reduced-risk claim.
That distinction matters if you are comparing brands. A brand can be legally sold, and even FDA-authorized, without any permission to say it is lower risk than cigarettes.
What Research Shows About Pouches vs Cigarettes
Peer-reviewed work published in journals such as Tobacco Control and indexed on PubMed consistently finds that nicotine pouches contain far lower levels of harmful and potentially harmful constituents than cigarette smoke. That is also what FDA said in the June 2026 order: the evidence supported the claim for these products.
The key variable is combustion. Cigarettes burn tobacco and generate tar, carbon monoxide, formaldehyde, benzene and dozens of known carcinogens. Research attributes most smoking-related disease to that combustion chemistry rather than to nicotine alone. Nicotine pouches are made of plant fiber, nicotine, flavorings and pH adjusters, and they produce no smoke.
Pouches are still not harmless. Nicotine is addictive, it raises heart rate and blood pressure, and oral use can irritate the gum and mouth tissue (gum irritation, side effects overview). Pregnant individuals and people with heart conditions face additional risk. For nicotine content comparisons, see How Much Nicotine: ZYN vs. Cigarette and Is ZYN Stronger Than a Cigarette?.
Who Should Consider Nicotine Pouches (Age 21+)
This article is informational and not medical advice. Consult a healthcare professional before using any tobacco or nicotine product.
For adults 21 and older who currently smoke, the FDA's modified risk finding is directly relevant: switching completely to the covered products lowers risk compared with continuing to smoke. Switching completely matters. Dual use keeps the cigarette exposure.
For adults 21 and older who do not use nicotine, FDA and CDC recommend against starting. There is no health reason to begin using nicotine, and pouches are not a wellness product.
The Bottom Line
The honest answer to "is ZYN better than smoking" is now more concrete than it was a year ago, and more limited than the marketing suggests. FDA has ruled that, for 20 specific ZYN products in 3 mg and 6 mg, a claim of lower risk compared with cigarettes is scientifically supported. For adults who smoke and are looking to stop combusting tobacco, that is a meaningful regulatory finding.
It is not a safety verdict. It does not extend to ZYN ULTRA, to other brands, or to anyone who does not already use nicotine. And it says nothing about quitting: if cessation is the goal, the FDA-approved options are nicotine replacement therapy and prescription treatment, and a clinician is the right person to map that out.